#SFHS2616862AFrance adds Cochlear Nucleus Nexa implants and processors to the reimbursable products list
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France makes several Cochlear France cochlear implant products eligible for reimbursement under the national health insurance product list. The additions include NUCLEUS NEXA cochlear implants and NUCLEUS 8 NEXA, NUCLEUS KANSO 3, and NUCLEUS KANSO 3 NEXA sound processors, with listed product codes, covered indications, compatible implants, and covered references. The measure mainly affects hospitals, hearing implant centers, audiology teams, patients with severe to profound hearing loss, and Cochlear France. Coverage applies to specified hearing rehabilitation cases, including severe to profound bilateral sensorineural hearing loss after conventional hearing aids fail, and certain severe to profound unilateral cases with disabling tinnitus after other systems fail. For at least one listed processor, reimbursement runs until 28 February 2029.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds specified Cochlear NUCLEUS NEXA implants and NUCLEUS sound processors to France’s reimbursable products and services list.
- Defines the covered hearing rehabilitation indications, including severe to profound bilateral hearing loss and certain unilateral cases with disabling tinnitus.
- Sets product-specific conditions such as compatible implants, covered references, renewal rules after warranty, and at least one reimbursement end date of 28 February 2029.
Obligations
What this law requires
Only claim reimbursement for the COCHLEAR NUCLEUS 8 NEXA CP 1110 sound processor when used for covered hearing rehabilitation indications: severe to profound bilateral sensorineural hearing loss after failure or ineffectiveness of conventional acoustic hearing aids, or severe to profound unilateral hearing loss with disabling tinnitus after failure or ineffectiveness of CROS or bone-anchored systems.
Do not claim reimbursement for NUCLEUS NEXA processors with the NUCLEUS ABI brainstem implant, because NEXA processors are not compatible with the NUCLEUS ABI implant listed on the reimbursable products list.
For NUCLEUS 8 NEXA CP 1110, submit reimbursement only for the listed covered references for initial implantation and renewal, separated by adult and child references as specified in the order.
Renewal reimbursement for the processor beyond the warranty period is only available when degradation of auditory or non-auditory performance caused by the processor is observed.
Reimbursement coverage for the NUCLEUS 8 NEXA CP 1110 processor ends on 28 February 2029 unless renewed or amended by a later measure.